Akcea Therapeutics Inc (AKCA)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: PHARMACEUTICAL PREPARATIONS

22 BOSTON WHARF RD BOSTON, MA 02210

Akcea Therapeutics, Inc. operates as a late stage biopharmaceutical company. The Company develops and commercializes drugs for the treatment of patients with cardiometabolic diseases caused by lipid disorders. Akcea Therapeutics serves patients worldwide.

Data as of 2020-05-30
Market Cap1.512 Billion Shares Outstanding101.509 Million Avg 30-day Volume201.671 Thousand
P/E Ratio Dividend Yield EPS-0.29
Price/Sales4.438 Price cash flow ratio14.5 Price free cash flow ratio15.3
Book Value5.02 Price to Tangible Book3.58 Alpha
Short Interest Ratio % Short Interest to Float R-squared
BETA 52-week High/Low25.66 / 8.0 Stddev
View SEC Filings from AKCA instead.

View recent insider trading info

Funds Holding AKCA (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding AKCA BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

PRICE MICHAEL DENNIS CHIEF FINANCIAL OFFICER

  • Officer
0 2020-05-18 2

YANNI BARBARA

  • Director
0 2020-05-14 3

SMITH SANDFORD D

  • Director
0 2020-05-13 2

PARSHALL B LYNNE

  • Director
0 2020-05-13 2

YANG MICHAEL J. EVP AND CCO

  • Officer
5,204 2020-04-29 3

PATTERSON JOSHUA F. GENERAL COUNSEL

  • Officer
27,114 2020-04-15 4

HOCHBERG ELAINE

  • Director
0 2020-04-13 2

KLEIN JOSEPH III

  • Director
0 2020-04-13 3

SALZMAN AMBER

  • Director
0 2020-04-13 3

CROOKE STANLEY T EXEC CHAIRMAN OF THE BOARD

  • Officer
  • Director
747,907 2020-03-25 0

O'DEA LOUIS CHIEF MEDICAL OFFICER

  • Officer
61,602 2020-03-23 5

MCDEVITT DAMIEN CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
245,783 2020-03-23 4

JENNE KYLE CHIEF COMMERCIAL OFFICER

  • Officer
52,732 2020-03-23 4

HOWARTH ALEX G. CHIEF OPERATING OFFICER

  • Officer
66,800 2020-03-19 3

HOUGEN ELIZABETH L SVP, FINANCE & CFO

  • Officer
32,374 2020-02-29 0

SOTEROPOULOS PAULA

  • Director
4,486 2020-02-27 1

MACLEAN MICHAEL F CHIEF FINANCIAL OFFICER

  • Officer
48,000 2020-01-15 3

MOSCICKI RICHARD A

  • Director
0 2019-12-19 1

IONIS PHARMACEUTICALS INC

  • 10% Owner
77,094,682 2019-12-17 1

BOYCE SARAH

  • Director
0 2019-10-15 2

GOLDBERG JEFF MARC CHIEF OPERATING OFFICER

  • Officer
156,631 2019-09-26 2

FITZGERALD EDWARD M

  • Director
0 2019-06-14 1

GABRIELI CHRISTOPHER

  • Director
0 2019-06-14 1

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Share Price Acquired or Disposed Shares Owned Following Transaction Combined shares owned after filing Direct/Indirect Ownership 10b-5

PRICE MICHAEL DENNIS - Officer CHIEF FINANCIAL OFFICER

2020-05-18 A 50,000 a 50,000 50,000.00 direct

PRICE MICHAEL DENNIS - Officer CHIEF FINANCIAL OFFICER

2020-05-18 A 300,000 a 300,000 50,000.00 direct

PATTERSON JOSHUA F. - Officer GENERAL COUNSEL

2020-04-15 A 12,500 a 27,114 27,114.00 direct

YANNI BARBARA - Director

2020-04-13 A 26,400 a 26,400 0.00 direct

PARSHALL B LYNNE - Director

2020-04-13 A 26,400 a 26,400 0.00 direct

SMITH SANDFORD D - Director

2020-04-13 A 26,400 a 26,400 0.00 direct

HOCHBERG ELAINE - Director

2020-04-13 A 26,400 a 26,400 0.00 direct

KLEIN JOSEPH III - Director

2020-04-13 A 26,400 a 26,400 0.00 direct

YANG MICHAEL J. - Director

2020-04-13 A 26,400 a 26,400 0.00 direct

SALZMAN AMBER - Director

2020-04-13 A 26,400 a 26,400 0.00 direct

Elevate your investments